-
eCRF Data Entry Delays: A Compliance Risk Frequently Underestimated
There is a scenario that everyone working in clinical research knows well. The site is under pressure, priorities keep shifting, and the electronic Case Report Form — which should reflect the real-time status of the study — stops being updated. The data exists: it is in the source documents, often correctly recorded. But it does…
-
PMCF under MDR: from regulatory obligation to competitive advantage
In many medical device companies, Post-Market Clinical Follow-up (PMCF) is still seen as a burden — a bureaucratic requirement introduced by the EU MDR (EU 2017/745) that adds cost and pressure to already overloaded regulatory teams. That view is increasingly short-sighted.Companies that treat PMCF purely as compliance are missing a significant strategic opportunity. The MDR…
-
Real-World Evidence and MDR: why post-market data often matters more than trials
There is a paradox in medical device research that is rarely discussed openly. The most controlled, expensive and rigorously monitored method of generating clinical evidence (the interventional trial) often produces evidence that becomes less useful once the device enters real clinical practice. Clinical trials typically ask: Does the device work under optimal conditions, with selected…
-
Innovative medical device in 2026: how to build an evidence strategy that holds…without drowning in rework
There’s a sentence we hear often from founders, Clinical Affairs and Regulatory teams: “We have a strong device, but we’re afraid of losing time.” Not time spent working.Time lost to rework, the kind that appears halfway through a study, when you realize it started… but wasn’t solid enough. Studies don’t fail because there’s a lack…
-
Risk-based means protecting what matters most
In clinical research, risk-based approaches are everywhere: they appear in protocols, monitoring plans, and quality systems. But there is a growing misunderstanding. Many organizations treat risk-based as a justification to reduce activities: fewer checks, lighter processes, less on-site monitoring. The goal is often simple: cut time and cost. Technically and regulatorily, this interpretation is wrong.…
-
Digital twins in Clinical trials: a new way of designing studies
In the past year, Digital twin has become one of the most overused terms in healthcare innovation. It appears in conference slides, CRO strategy decks, and investor presentations, often described as a virtual copy of a patient, ready to be tested like an avatar in a simulation. But the reality is less cinematic and far…
-
PMS and Real-World Data: when real evidence begins after the study
When a clinical study changes its nature For a long time, post-market was treated as a phase that comes after the study.A necessary surveillance activity, but separate from clinical research itself. Today, that approach no longer works. Medical devices, especially digital and connected ones, continue to generate data long after the last patient visit.And that…
-
When compliance isn’t enough: when is a clinical study truly safe?
Many clinical studies begin with a reassuring sense of security: the protocol is approved, the documentation is complete, regulatory requirements are met. Yet anyone who actually works in clinical research knows this: initial compliance is not the same as safety. The real question is not whether a study is compliant today, it is what happens…
-
Post-Market 2.0: how continuous Real-World Evidence is redefining medical devices
There’s a silent but radical shift reshaping the value of medical devices, more than any new technology or algorithm. A shift born in real life: in patients’ routines, phones, homes, and clinical journeys. Its name is Real-World Evidence (RWE).And it is turning post-market from a formal requirement into a strategic engine of safety, performance, competitiveness,…
-
Patients are evolving faster than trials: why clinical data are falling behind
In clinical research, we speak often about patient-centricity. Yet in the past two years something unexpected has happened: patients’ real lives have become more digital, more monitored, and more interconnected than the trials designed to study them. The patient has changed.Their data pathways have not. Not because the industry lacks intent, but because traditional study…
